Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP/BGP Company Profiles - Data
Jump to navigation
Jump to search
Celera
Amgen
- Headquarters: Thousand Oaks, CA
- 16,900 employees (2008 Corporate report)
- History of acquisition:
- 1994 - Synergen, Inc.
- 2000 - Kinetix Pharmaceuticals, Inc.
- 2002 - Immunex Corporation
- 2004 - Tularik, Inc.
- 2006 - Abgenix, Inc.
- 2006 - Avidia, Inc.
- 2007 - Ilypsa, Inc.
- 2007 - Alantos Pharmaceuticals Holdings, Inc.
- Subsidiaries:
- Amgen Australia Pty Ltd.;
- Amgen N.V.; Amgen Canada Inc.;
- Amgen Greater China Ltd.;
- Amgen GmbH (Germany);
- Amgen S.A. (France);
- Amgen S.p.A. (Italy);
- Amgen K.K. (Japan);
- Amgen B.V. (Netherlands);
- Amgen-Biofarmaceutica (Portugal);
- Amgen S.A. (Spain);
- Amgen (Europe) AG (Switzerland);
- Kirin-Amgen, Inc. (Switzerland);
- Amgen Limited (U.K.);
- Amgen Sales Corporation (West Indies).
- Unlike many biotech companies, has been consistently profitable. Net profit in 2006 was US$2.9 Billion
- History: **Managed to turn itself from a drug research company into a pharmaceutical company while maintaining steady sales - extremely rare in the industry.
- Founded in 1980. By 1986 was starting to turn a profit, but did so not through drug development but through research partnerships with established pharma firms
- 1987, develop erythropoietin (EPO), which stimulates red blood cell creation. Sold the marketing rights to Johnson&Johnson
- Epogen proves to hugely popular - over $250m in sales in 1991 alone
- Between 1992 and 1996, Amgen's R&D budget goes from $182 million to $663 million
- It has ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline as of 2009
- drugs include: Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara and Nplate
- As a side-result of this research, also publishes in academic journals
- Others/Notes:
- Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed
- Seems to be engaging in some instances of open-ended research with universities. e.g., collaboration with MIT's Whitehead institute
- Further instances of academic collaboration here
- The results of some scientific collaborations are being released into the commons
- It says its committed to sharing clinical testing results as soon as possible
Genentech
- Headquarters: South San Francisco
- 11,000 employees ("Genentech," Wikipedia)
- Owned by Swiss pharma company Hoffman - La Roche (Hoffman-La Rouche)
- synthetic human insulin was their first famous product, many others produced using the Boyer-Cohen rDNA process
- Papers by company employees
- Others/Notes:
- Collaborated with Apple to create Open Source search engine for protein and DNA sequences called Apple/Genentech BLAST
- Hoffman-La Rouche is engaging in academic collaboration to study the safety of InnoMed PredTox ("Hoffman-La Rouche," Wikipedia)
- In general, this seems to be a company that encourages its scientists to publish
- examples of papers
- Video of Genentech's Joe McCracken explaining incentives to publish
- It has four-year post-doctoral program and also offers Clinical Research Fellowships
- Supplies reagents for other research organizations' work
- Worked with the American Academy of Ophthalmology and the American Society of Retina Specialists to develop guidelines and answer questions about Avastin
- Has a separate board to advise the company on issues of scientific research
- Company gives researchers 20% free time to work on projects of their own
- VP for business development says the organization survives through science, not marketing.
- Collaboration with UC San Diego Scientists
- Funds undergraduate research programs through the Genentech Foundation
- Provids infrastructure support for UCSF
- Collaboration with Rockefeller University to look at therapeutic antibody potency
Genzyme
- Headquarter Cambridge
- 2007, US$2.89B operating income, $3.81B revenue ("Genzyme," Wikipedia)
- Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue
- Renagel, for dialysis patients
- Fabrazyme, for Fabry's disease
- Other/Notes:
- Develops community support groups for victims of the diseases it treats, such as Fabry Community and other at Genzyme Disease Education/Research/Support Sites
- Has established for victims of Gaucher's disease
- All company-sponsored clinical trials registered [www.clinicaltrials.gov Clinical Trials] and at Genzyme Clinical Research
- Partial catalog of researchers' publications
- Give grants for science education and health-services in local communities
- Building outreach into China. Will establish research center there by 2010.
Gilead Sciences
- Headquarters: Foster City, California
- 3,400 hundred employees as of 2009
- Growth based in large part on acquisition of other companies
- Products for HIV/AIDS, respiratory and heart conditions, and liver disease
- Over a dozen drugs in the development pipeline, Phase I or later
- Acquisition history:
- 1990 reaches agreement with Glaxo to research and develop "antisense" -- genetic code blockers
- Goes public in 1992
- 1996 - first commercial product, Vistide, treats cytomegalovirus
- 1999 - acquires NeXstar Pharmaceuticals
- 2003 acquires Triangle Pharmaceuticals
- 2006, FDA approves Atripla for HIV-victims
- 2006 acquires Corus Pharma, Inc.
- 2006 acquires Myogen, Inc.
- 2006 acquires Raylo Chemicals, a pharma producer - is Gilead Sciences trying to become a pharma company?
- Other/Notes:
- Gilead seems to have created an HIV/AIDS Clinical Cooperation Grant
- publishes the results of clinical trials
- Collaboration with UCSF on HIV targets
- Project to bring HIV/AIDS drugs to third-world
- Foundation for bringing health care to under-served communities
Biogen Idec
- Headquarters: Kendall Scquare, Cambridge
- from Wikipedia: commercial affiliates in "Germany, France, Spain/Portugal, UK/Ireland, the Benelux, Sweden, Denmark, Norway, Finland, and Austria"
- Research centers in San Diego and Research Triangle Park, N.C.
- Treatments for Multiple Sclerosis, Crohn's disease, and a treatment for non-Hodgkin's lymphoma which is co-marketed with Genentech
- Most revenue derived from Avonex, it's MS treatment
- 2003, Biogen and IDEC merge
- Others/Notes:
- Gives [1] educational grants to med schools
- Sponsors "Citi Biotech Day"
- Has US$100million venture capital fund to encourage Biotech research
- Cooperated with Genentech to research and produce lymphoma treatment
- Has the Biogen Idec Innovation Incubator (bi3), and has a history of buying start-ups ventures
- Provides Student labs for high school students in Cambridge and San Diego
Cephalon
Who
- 3,000 employees
What
- Leading product - Provigil, to treat sleep disorder
- Focus on Neurodegenerative diseases
- has acquired the following firms: CIMA Labs, Anesta, and Laboratoire Lafon
Where
- Frazer, PA
News
- Founded in 1987, CEO Frank Baldino, Jr., Ph.D
- Failure of neurodegenerative treatment in 1992 - discovered that the drug kept mice awake, turned it into Provigil in 1999 (Cephalon, "Our Story")
- 2008, sales of US$1.943 billion
- 2008 - Treanda - treatment for non-hodgkin's lymphoma - approved and launched
- Stock has posted double-digit earnings this year (Bennett "It's Wake-Up Time for a Drug Maker's Shares")
- 2009 - seeks approval for Nuvigil to treat Jet Lag (Kennedy, "Cephalon To Apply For FDA Approval For Nuvigil For Jet Lag")
- 2009 - studies suggest Nuvigil could also be used to treat Bipolar Depression (Medical News Today, "Cephalon Announces Positive Results From A Phase Two Study Of NUVIGIL In Bipolar Depression")
- 2009 - (unsubstantiated) gossip that Eli Lilly might consider purchasing Cephalon (Feuerstein, "What's on Lilly's Prescription Pad?") Further rumors of take-over: (Steven, "2 Potential Pharma M&A Targets: Cephalon and Genzyme")
- 2009 - bid to take over Australian biotech firm. Interest in its treatments for inflammatory diseases and cancer (Domain-B, "Cephalon opens bid for Aussie bio-technology firm Arana")
Commons-Based, Peer-Production, and Open Access News
- Interesting: Three areas for establishing collaborative studies (Cephalon, "Research Partnerships"):
- Pre-clinical studies - has simple online form for obtaining Cephalon products for pre-clinical studies. Response within a month.
- Cephalon-sponsored studies - can apply to work as an investigator in a Cephalon study
- Investigator Sponsored Studies (ISS) - investigator herself designs the trial, gets the regulatory approval, interprets and communicates the results. It appears that you just submit a proposal, and if approved, Cephalon will fund the study (Cephalon, "Going Further in Research")
- Also seems very open to potential business partnerships. All you have to do is send an email (Cephalon, "Business Collaboration")
- Negative test results are being used to further general research on Parkinson's disease (Cephalon, "Our Science")
- Corporate giving for health advocacy, science education, and community building in locations where Cephalon has offices (Cephalon, "Corporate Giving")
- 2006 - collaboration with Ambit Biosciences to research kinase inhibitors (B-Net, "Ambit Biosciences Announces Discovery and Development Collaboration with Cephalon, Inc. Focused on Kinase Inhibitors")
- Alzheimer's disease research collaboration with Scherring-Plough
- Collaboration with Abbott Laboratories to produce and develop Gabitril, an anti-epilepsy drug (PR Newswire, "Abbott Laboratories and Cephalon Sign Collaboration Agreement for Gabitril(R) (Tiagabine Hydrochloride) in the United States")
MedImmune
Celgene
Abraxis BioScience
ImClone Systems
IP Profile of Biggest for-profit companies in BGP
Biotechnology - Genomic and Proteomics
Main Page